Home / Featured

Antibody-Drug Conjugates

Targeted cytotoxic delivery: payload and linker design, the antigens that make a tumour addressable, and how ADCs perform once the obvious targets are taken.

10 articles in this topic

  • November 11, 2026Nature MedicineRetrospective analysis of TROPION-PanTumor01 and TROPION-Lung01 (NCT04656652, NCT03401385)

    A Computational Pathology Score for TROP2 Is Linked to Longer Survival on Datopotamab Deruxtecan, but Not Docetaxel, in a Retrospective NSCLC Analysis

    A retrospective analysis of TROPION-PanTumor01 and TROPION-Lung01 reports that TROP2 normalized membrane ratio (NMR), measured by AI-based image analysis of IHC-stained slides, was associated with longer survival on datopotamab deruxtecan (Dato-DXd) but not on docetaxel. In nonsquamous, non-actionable-genomic-alteration NSCLC (n = 221), median PFS with Dato-DXd was 7.2 versus 4.0 months in NMR-positive versus NMR-negative patients (HR 0.40, 95% CI 0.25–0.64).

  • September 11, 2026Journal of Clinical OncologyPhase III, open-label, randomized (NCT06968585)

    Trastuzumab Botidotin Extends PFS Versus T-DM1 (HR 0.39) in Previously Treated HER2-Positive Advanced Breast Cancer, With Immature Overall Survival Data

    In a phase III, open-label, randomized trial at 57 centers in China, 365 patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab and a taxane were randomized 1:1 to trastuzumab botidotin (n = 182) or trastuzumab emtansine (n = 183). Median PFS by blinded independent central review was 11.1 vs 4.4 months (HR 0.39; 95% CI, 0.30 to 0.51; nominal P < .0001), and objective response rate was 76.9% vs 53.0%.

  • October 25, 2026The New England Journal of MedicineOptiTROP-Lung06 (randomized phase 3), NCT06711900

    Sacituzumab Tirumotecan Plus Pembrolizumab Reaches a Median Progression-Free Survival of 15.0 vs 5.7 Months Against Chemotherapy Plus Pembrolizumab in PD-L1-Negative Advanced Nonsquamous NSCLC, With Overall Survival Still Immature: The Phase 3 OptiTROP-Lung06 Trial

    OptiTROP-Lung06 randomly assigned 455 previously untreated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer, without targetable genomic alterations and with a PD-L1 tumor proportion score below 1%, 1:1 to sacituzumab tirumotecan plus pembrolizumab (n = 229) or chemotherapy plus pembrolizumab (n = 226). After a median follow-up of 9.7 months, median progression-free survival by blinded independent central review was 15.0 vs 5.7 months (HR for progression or death 0.49; 95% CI 0.36 to 0.65; P<0.001).

  • October 7, 2026The OncologistRetrospective multicenter cohort (not a clinical trial; no registry ID)

    Concurrent Radiotherapy With Adjuvant T-DM1 Shows More Thrombocytopenia, Liver Enzyme Elevation and Early Lung Changes Than With Trastuzumab in a Retrospective, Non-Randomized Study of 133 Patients

    In a retrospective, multicenter study of 133 women with HER2-positive stage I-III breast cancer treated at four hospitals in Istanbul between 2010 and 2024, concurrent adjuvant radiotherapy with T-DM1 (n = 50) was associated with higher rates of any-grade thrombocytopenia (70% vs 36.1%; P < .001), ALT elevation (20% vs 4.8%; P = .008), AST elevation (24.5% vs 2.4%; P < .001) and early pulmonary toxicity (48.8% vs 24.1%; P = .017) than concurrent radiotherapy with trastuzumab (n = 83).

  • July 24, 2026Journal of Clinical OncologyBL-B01D1-101 (Phase Ib expansion cohort, single arm)

    Iza-bren Shows a 48.1% Response Rate in Relapsed Extensive-Stage Small Cell Lung Cancer, but 75% Had Grade 3 or Higher Treatment-Related Adverse Events in a Single-Arm Phase Ib Cohort

    BL-B01D1-101 is an open-label, multicenter phase I study of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR-HER3 bispecific antibody-drug conjugate carrying a topoisomerase I inhibitor payload. The phase Ib extensive-stage small cell lung cancer (SCLC) cohort treated 52 patients who had progressed after platinum-based chemotherapy and a PD-(L)1 inhibitor.

  • September 12, 2026New England Journal of MedicineTAISHAN-302

    Tam-Peli Cuts Death Risk 54% Versus Topotecan in Relapsed Small-Cell Lung Cancer

    The phase 3 TAISHAN-302 trial's interim analysis reports that the B7-H3-targeted antibody-drug conjugate tambotatug pelitecan (Tam-Peli) significantly extends overall and progression-free survival compared with topotecan in patients with small-cell lung cancer (SCLC) that relapsed after platinum-based chemotherapy.

  • August 27, 2026Clinical Cancer ResearchNCT02675829

    T-DM1 Shows Strongest Activity in Salivary Gland Cancer in HER2-Amplified Basket Trial

    A single-center, non-randomized phase 2 basket trial tested ado-trastuzumab emtansine (T-DM1) across five disease-specific cohorts of HER2-amplified solid tumors, asking whether a shared molecular driver predicts benefit from a HER2-targeted antibody-drug conjugate regardless of tumor origin.

  • August 3, 2026Clinical Cancer ResearchNCT04251416 (investigator-initiated, single-center)

    Sacituzumab Govitecan Shows 28% Response Rate in Recurrent Endometrial Cancer

    A single-center, investigator-initiated Phase II trial using a Simon two-stage design tested sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, in 50 evaluable patients with recurrent or persistent endometrial cancer who had progressed after platinum-based chemotherapy, enrolled between March 2020 and December 2024.

  • July 13, 2026Nature MedicineDYP688 First-in-Human Study (NCT05415072)

    First-in-Human ADC Shows Early Activity in GNAQ/GNA11-Mutant Uveal Melanoma

    Phase 1, first-in-human dose-escalation trial of DYP688 — an antibody-drug conjugate that targets the melanocyte antigen PMEL and delivers a Gq/11 signaling inhibitor payload — in 66 patients with metastatic uveal melanoma and other GNAQ/GNA11-mutant melanomas, a population largely excluded from the only approved therapy for this disease.

  • March 15, 2026New England Journal of MedicineOptiTROP-Lung04 (NCT05870319)

    Sacituzumab Tirumotecan Demonstrates Superior Progression-Free and Overall Survival in EGFR-TKI–Resistant Non–Small-Cell Lung Cancer

    The Phase III OptiTROP-Lung04 trial randomized 376 patients with EGFR-mutated advanced NSCLC that progressed after EGFR-TKI therapy to sacituzumab tirumotecan (sac-TMT) monotherapy or platinum-based chemotherapy

Cancer types covered: Lung Cancer · Breast Cancer · Salivary Gland Cancer · Colorectal Cancer · Endometrial Cancer · Melanoma